As­traZeneca to ex­pand its Syd­ney fa­cil­ity

BioSpectrum (Asia) - - Finance News -

Phar­ma­ceu­ti­cal gi­ant As­traZeneca will spend $100 mil­lion ex­pand­ing its Syd­ney fa­cil­ity, a move it says will add 60 jobs and boost ex­ports to more than $2.4 bil­lion over the next four years.

The com­pany said the in­vest­ment would fund three spe­cialised pro­duc­tion lines at the North Ryde fa­cil­ity for in­no­va­tive res­pi­ra­tory medicines. As­traZeneca has in­vested $105m at the fa­cil­ity in the last five years. The three new spe­cialised pro­duc­tion lines are in ad­di­tion to eight ex­ist­ing spe­cialised lines at the site.

Mel­bourne-based spe­cial­ist ma­chine de­sign­ers Andrew Don­ald De­sign En­gi­neer­ing will build each new pro­duc­tion line and the ma­chines will take a team of 36 peo­ple over 12 months to pro­duce. Each pro­duc­tion line has the ca­pac­ity to pro­duce over 70 mil­lion units per year of Pul­mi­cort Re­spules, a medicine for pa­tients with asthma. The medicine is pro­duced in Aus­tralia for ex­port mar­kets, in­clud­ing China. It is pre­dicted that by 2025 As­traZeneca’s site will be pro­duc­ing over one bil­lion re­spules.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.